Exagen Inc. (XGN) NASDAQ
2.76
+0.03(+1.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.76
+0.03(+1.10%)
Currency In USD
| Previous Close | 2.73 |
| Open | 2.69 |
| Day High | 2.82 |
| Day Low | 2.66 |
| 52-Week High | 12.23 |
| 52-Week Low | 2.59 |
| Volume | 291,474 |
| Average Volume | 318,962 |
| Market Cap | 66.39M |
| PE | -2.97 |
| EPS | -0.93 |
| Moving Average 50 Days | 3.12 |
| Moving Average 200 Days | 6.93 |
| Change | 0.03 |
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
GlobeNewswire Inc.
Feb 24, 2026 2:00 PM GMT
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10
Exagen Inc. Announces Select Preliminary 2025 Financial Results
GlobeNewswire Inc.
Jan 11, 2026 8:00 PM GMT
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
GlobeNewswire Inc.
Oct 23, 2025 1:15 PM GMT
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Conver